These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8866702)

  • 21. Effects of ketamine on precipitated opiate withdrawal.
    Jovaisa T; Laurinenas G; Vosylius S; Sipylaite J; Badaras R; Ivaskevicius J
    Medicina (Kaunas); 2006; 42(8):625-34. PubMed ID: 16963828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis.
    Schulteis G; Markou A; Gold LH; Stinus L; Koob GF
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1391-8. PubMed ID: 7996451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circling behavior after narcotic drugs and during naloxone-precipitated abstinence in rats with unilateral nigral lesions.
    Iwamoto ET; Loh HH; Way EL
    J Pharmacol Exp Ther; 1976 Jun; 197(3):503-16. PubMed ID: 945346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Aug; 250(2):485-91. PubMed ID: 2760839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of anaesthetic agents in interference of naloxone-induced opiate-withdrawal are dose-dependent in opiate-dependent rats.
    Streel E; Dan B; Antoniali V; Clement B; Campanella S; Hanak C; Vanderlinden P; Pelc I; Verbanck P
    Life Sci; 2005 Jun; 77(6):650-5. PubMed ID: 15921996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity.
    Martin JR; Takemori AE
    J Pharmacol Exp Ther; 1987 Apr; 241(1):48-55. PubMed ID: 3572795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Jan; 248(1):127-34. PubMed ID: 2913267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-adrenergic antagonists attenuate somatic and aversive signs of opiate withdrawal.
    Harris GC; Aston-Jones G
    Neuropsychopharmacology; 1993 Dec; 9(4):303-11. PubMed ID: 7905738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Different roles of the spinal protein kinase C alpha and gamma in morphine dependence and naloxone-precipitated withdrawal].
    Cao JL; Ding HL; He JH; Zhang LC; Wang JK; Zeng YM
    Sheng Li Xue Bao; 2005 Apr; 57(2):161-8. PubMed ID: 15830100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1988 Aug; 246(2):441-8. PubMed ID: 2457074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenosine triphosphate blocks opiate withdrawal symptoms in rats and mice.
    Gomaa AA; Moustafa SA; Farghali AA
    Pharmacol Toxicol; 1989 Jan; 64(1):111-5. PubMed ID: 2755901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in dopaminergic neurotransmission do not alter somatic or motivational opiate withdrawal-induced symptoms in rats.
    Caillé S; Rodriguez-Arias M; Minarro J; Espejo EF; Cador M; Stinus L
    Behav Neurosci; 2003 Oct; 117(5):995-1005. PubMed ID: 14570549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity.
    Charney DS; Redmond DE; Galloway MP; Kleber HD; Heninger GR; Murberg M; Roth RH
    Life Sci; 1984 Sep; 35(12):1263-72. PubMed ID: 6482651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenylmethanesulfonyl fluoride, a serine protease inhibitor, suppresses naloxone-precipitated withdrawal jumping in morphine-dependent mice.
    Nemoto W; Sato T; Nakagawasai O; Yaoita F; Silberring J; Tadano T; Tan-No K
    Neuropeptides; 2013 Jun; 47(3):187-91. PubMed ID: 23290539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies.
    Windh RT; Little PJ; Kuhn CM
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1361-74. PubMed ID: 7791109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double dissociation in the neural substrates of acute opiate dependence as measured by withdrawal-potentiated startle.
    Harris AC; Atkinson DM; Aase DM; Gewirtz JC
    Neuroscience; 2006; 139(4):1201-10. PubMed ID: 16600512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users.
    Lubman D; Koutsogiannis Z; Kronborg I
    Drug Alcohol Rev; 2003 Dec; 22(4):433-6. PubMed ID: 14660133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.